Among malignant lesions with available molecular subtype classification (n = 68), iCAD scores varied across subtypes, with higher median values observed in triple-negative cancers (98% [IQR, 34–99%]), Luminal B cancers (89% [IQR, 63–95%]), and Luminal A cancers (85% [IQR, 28–95%]) compared with Luminal B/HER2+ (78% [IQR, 58–91%]) and HER2-positive (51% [44–60%]) tumors. This evidence concerns the gene ERBB2 and cancer.